低剂量利伐沙班联合或不联合阿司匹林与缺血性卒中亚型的关联:COMPASS试验二次分析
该研究为COMPASS随机临床试验的二次分析,纳入27 395例稳定动脉粥样硬化性血管病患者,评估低剂量利伐沙班(2.5 mg每日两次)联合阿司匹林(100 mg每日一次)对比单用阿司匹林对缺血性卒中亚型的影响。
要点
- 联合治疗显著降低心源性栓塞性卒中风险(HR 0.40,95%CI 0.20-0.78)。
- 联合治疗显著降低不明来源栓塞性卒中风险(HR 0.30,95%CI 0.12-0.74)。
- 对颈动脉狭窄>50%相关卒中无显著影响(HR 0.85,95%CI 0.45-1.60)。
核心结论
- 对于系统性动脉粥样硬化患者,低剂量利伐沙班联合阿司匹林与心源性栓塞性卒中和不明来源栓塞性卒中的大幅显著减少相关。
研究设计与样本
- COMPASS试验的二次分析,为多中心、双盲、随机、安慰剂对照研究,于2013年3月12日至2016年5月10日在33个国家进行。
- 共随机27 395例稳定动脉粥样硬化性血管病患者,随访至2017年2月6日,所有首次缺血性卒中及不确定卒中按TOAST标准裁定。
- 分析采用意向性治疗原则,统计分析方法于2013年3月12日至2017年2月6日进行。
主要发现
- 共291例患者发生缺血性卒中(66例女性;平均[SD]年龄69.4[8.5]岁;43例[14.8%]有既往非腔隙性卒中)。
- 研究期间49例患者(16.8%)被诊断为心房颤动。
- 按TOAST标准,59例卒中(20.3%)为心源性栓塞性,54例(18.6%)为同侧颈内动脉狭窄>50%所致,42例(14.4%)评估阴性符合不明来源栓塞性卒中标准,21例(7.2%)为小血管病所致。
临床怎么用
- 对于系统性动脉粥样硬化患者,低剂量利伐沙班联合阿司匹林可能减少心源性栓塞性卒中和不明来源栓塞性卒中。
- 该结果为探索性分析,在影响临床实践前需独立确认。
局限性
- 该研究为二次分析,结果属探索性,需独立确认后方可影响临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) randomized clinical trial was stopped early owing to the efficacy of low-dose rivaroxaban plus aspirin in preventing major cardiovascular events. The main reason for early trial termination was the effect of combination therapy on reducing ischemic strokes. OBJECTIVE: To analyze the association between low-dose rivaroxaban with or without aspirin and different ischemic stroke subtypes. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of a multicenter, double-blind, randomized, placebo-controlled study that was performed in 33 countries from March 12, 2013, to May 10, 2016. Patients with stable atherosclerotic vascular disease were eligible, and a total of 27 395 participants were randomized and followed up to February 6, 2017. All first ischemic strokes and uncertain strokes that occurred by this date were adjudicated using TOAST (Trial of Org 10172 in Acute Stroke Treatment) criteria. The analysis of ischemic stroke subtypes was evaluated using an intention-to-treat principle. Statistical analysis was performed from March 12, 2013, to February 6, 2017. INTERVENTIONS: Participants received rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban (5 mg twice a day), or aspirin (100 mg once a day). MAIN OUTCOMES AND MEASURES: Risk of ischemic stroke subtypes during follow-up. RESULTS: A total of 291 patients (66 women; mean [SD] age, 69.4 [8.5] years; 43 [14.8%] had a previous nonlacunar stroke) experienced an ischemic stroke. During the study, 49 patients (16.8%) received a diagnosis of atrial fibrillation. Applying TOAST criteria, 59 strokes (20.3%) were cardioembolic, 54 strokes (18.6%) were secondary to greater than 50% stenosis of the ipsilateral internal carotid artery, 42 strokes (14.4%) had a negative evaluation that met criteria for embolic stroke of undetermined source, and 21 strokes (7.2%) were secondary to small vessel disease. There were significantly fewer cardioembolic strokes (hazard ratio [HR], 0.40 [95% CI, 0.20-0.78]; P = .005) and embolic strokes of undetermined source (HR, 0.30 [95% CI, 0.12-0.74]; P = .006) in the combination therapy group compared with the aspirin-only group. A trend for reduction in strokes secondary to small vessel disease (HR, 0.36 [95% CI, 0.12-1.14]; P = .07) was not statistically significant. No significant difference was observed between the 2 groups in strokes secondary to greater than 50% carotid artery stenosis (HR, 0.85 [95% CI, 0.45-1.60]; P = .61). Rivaroxaban, 5 mg, twice daily showed a trend for reducing cardioembolic strokes compared with aspirin (HR, 0.57 [95% CI, 0.31-1.03]; P = .06) but was not associated with reducing other stroke subtypes. CONCLUSIONS AND RELEVANCE: For patients with systemic atherosclerosis, low-dose rivaroxaban plus aspirin was associated with large, significant reductions in cardioembolic strokes and embolic strokes of undetermined source. However, these results of exploratory analysis need to be independently confirmed before influencing clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01776424.
引用
- Perera KS, Ng KKH, Nayar S, et al. Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. JAMA Neurol. 2020. PMID: 31524941. doi:10.1001/jamaneurol.2019.2984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。